Exicure, Inc. Stock News

Exicure Inc. (NASDAQ:XCUR)’s traded shares stood at 20.51 million during the last session, with the company’s beta value hitting 1.19. At the close of trading, the stock’s price was $0.23, to imply a decrease of -12.85% or -$0.03 in intraday trading. The XCUR share’s 52-week high remains $2.68, putting it -1065.22% down since that peak … Boom Or Bust: What Are Exicure Inc.’s (NASDAQ:XCUR) Future Prospects? Read More »

Gainers ECMOHO Limited (NASDAQ: MOHO ) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP ) shares jumped 39.2% to close at $2.06 after dipping 37% on Tuesday. Nordstrom, Inc. (NYSE: JWN ) shares jumped 37.8% to settle at $26.93 after the company reported better-than-expected Q4 EPS and sales results. The company also issued FY22 guidance. Regulus Therapeutics Inc. (NASDAQ: RGLS ) gained 35.6% to close at $0.3050. Indonesia Energy Corporation Limited (NASDAQ: INDO ) surged 34.5% to close at $14.50. Trevi Therapeutics, Inc. (NASDAQ: TRVI ) gained 32% to settle at $1.15. Arlo Technologies, Inc. (NYSE: ARLO ) rose 28.9% to close at $11.19 after the company reported better-than-expected Q4 results. The company also issued Q1 sales guidance above analyst estimates. Rocky Brands, Inc. (NASDAQ: RCKY ) climbed 26.6% to close at $47.47 following better-than-expected Q4 results. China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC ) gained 26.1% to close at $0.2181.

Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Toll-Like Receptor Agonist treatment scenario include InDex Pharmaceuticals, Mologen, Exicure, Birdie Biopharmaceuticals, Seven and Eight Biopharmaceuticals, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Hoffman-La-Roche, Ascendis Pharma, Nektar therapeutics, BioNTech, Highlight Therapeutics, PrEP Biopharm, TriSalus Life Sciences, Gilead Sciences, Tallac Therapeutics, Inc., ALX Oncology Holdings Inc., Checkmate Pharmaceuticals, AIM ImmunoTech, Scopus BioPharma, BrightPath Biotherapeutics, NapaJen Pharma, Ena Respiratory, Revelation Biosciences, Immune Design, Protara Therapeutics, Galderma, Bolt Biotherapeutics, Jiangsu Hengrui Medicine Co., Novartis, Elicio Therapeutics, Statera BioPharma, and many others.

Final Deadline Alert: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm

NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Exicure, Inc. (NASDAQ: XCUR) between March 11, 2021 and November 15, 2021, inclusive (the “Class Period”) of the important February 11, 2022 lead plaintiff deadline.

Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed aga

Deadline Friday Notice: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm

Deadline Friday Alert: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm

NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Exicure securities between January 7, 2021 and December 10, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/xcur .

NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Exicure, Inc. (NASDAQ: XCUR) between March 11, 2021 and November 15, 2021, inclusive (the Class Period) of the important February 11, 2022 lead plaintiff deadline.

Friday Deadline Reminder: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm

NEW YORK, Feb. 3, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Exicure, Inc. (NASDAQ: XCUR) between March 11, 2021 and November 15, 2021, inclusive (the "Class Period") of the important February 11, 2022 lead

Check these Reddit penny stocks out for your watchlist right now The post Popular Reddit Penny Stocks to Watch In February 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

Check these Reddit penny stocks out for your watchlist right now The post Popular Reddit Penny Stocks to Watch In February 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | Pen